EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer

Munenobu Kashiwa, Kensuke Moriwaki

Clinical Drug Investigation · 2026-11 · 46 (11) · 1313-1325

DOI: 10.1007/s40261-026-01591-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, online erschienen am 28.09.2026. Verfasst von Munenobu Kashiwa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan Un…. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4, Health Care Costs. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Ritsumeikan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are standard first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, yet the cost architecture across the full treatment trajectory remains poorly characterized. This study aimed to characterize phase-specific healthcare costs using a Japanese nationwide claims database. METHODS: We conducted a retrospective cohort study using the DeSC-IQVIA integrated Claims data (April 2014-May 2025). Patients with HR+/HER2- metastatic breast cancer who initiated first-line CDK4/6i were identified. Healthcare costs were decomposed into drug, non-drug inpatient, and non-drug outpatient components across eight treatment phases. Death-anchored analysis evaluated cost structure over the final 12 months of life among decedents. RESULTS: Among 5435 patients (median age 72.3 years), active treatment phases showed drug-dominated cost structures: first-line per-patient per-month (PPPM) cost was 482,936 Japanese yen (JPY) (drug 85%-90%), second-line 361,615 JPY (81%), and extended chemotherapy 255,922 JPY (66%). A marked inversion occurred in the palliative phase (PPPM 233,824 JPY; drug 11%, inpatient 70%) and terminal phase (PPPM 412,149 JPY; drug 17%, inpatient 69%). Death-anchored analysis of 1111 decedents identified a transition 2 months before death, when inpatient costs first exceeded drug costs. Individual fixed-effects models estimated the CDK4/6i-associated cost increment at 239,815 JPY/month (p < 0.001), corresponding to a total treatment-associated cost of 2.99 million JPY per patient. CONCLUSIONS: The cost architecture of CDK4/6i-treated metastatic breast cancer follows a predictable trajectory from drug-dominated active treatment to hospitalization-dominated end-of-life care, with a structural transition approximately 2 months before death. These findings support phase-specific healthcare resource allocation and economic modeling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Health Care CostsProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleRetrospective StudiesErb-b2 Receptor Tyrosine KinasesAgedJapanMiddle AgedAged, 80 and overNeoplasm MetastasisReceptors, EstrogenReceptors, Progesterone

Substanzen

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCDK6 protein, humanCDK4 protein, humanERBB2 protein, humanReceptors, EstrogenAntineoplastic AgentsReceptors, Progesterone

Autor:innen und Institutionen

  • Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan. mkashiw…
  • Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan.
  • Division of Health Policy and Management, Department of Biomedical Science, College of Life Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Ritsumeikan University

Zitieren

APA

Kashiwa, M., & Moriwaki, K. (2026). Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer. Clinical Drug Investigation, 46(11), 1313-1325. https://doi.org/10.1007/s40261-026-01591-7

Vancouver

Kashiwa M, Moriwaki K. Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer. Clinical Drug Investigation. 2026;46(11):1313-1325. doi:10.1007/s40261-026-01591-7

BibTeX
@article{Kashiwa2026,
  author = {Kashiwa, Munenobu and Moriwaki, Kensuke},
  title = {Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer},
  journal = {Clinical Drug Investigation},
  year = {2026},
  volume = {46},
  number = {11},
  pages = {1313--1325},
  doi = {10.1007/s40261-026-01591-7}
}
Kostenlos starten →